CTOs on the Move

Sucampo

www.sucampo.com

 
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.sucampo.com
  • 805 King Farm Boulevard Suite 550
    Rockville, MD USA 20850
  • Phone: 301.961.3400

Executives

Name Title Contact Details

Similar Companies

Psychiatric Medical Care

Through the use of telepsychiatry technology, we’re able to help our partner facilities see patients more efficiently and in a wide variety of locations.

PAR Pharmaceuticals

PAR Pharmaceuticals is a Woodcliff Lake, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSPEQ

BioSPEQ is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biotechlogic

Biotechlogic is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syros

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.